Andrew G S Warrilow
Overview
Explore the profile of Andrew G S Warrilow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
939
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Price C, Warrilow A, Rolley N, Parker J, Thoss V, Kelly D, et al.
PLoS One
. 2022 Mar;
17(3):e0265227.
PMID: 35312722
The cytochrome P450 CYP168A1 from Pseudomonas aeruginosa was cloned and expressed in Escherichia coli followed by purification and characterization of function. CYP168A1 is a fatty acid hydroxylase that hydroxylates saturated...
2.
Warrilow A, Parker J, Price C, Rolley N, Nes W, Kelly D, et al.
Int J Antimicrob Agents
. 2019 Jul;
54(4):449-455.
PMID: 31310805
Here we report the first evaluation of isavuconazole inhibition of Aspergillus fumigatus CYP51 and thus sterol biosynthesis in the fungus. Voriconazole and isavuconazole both bound tightly to recombinant A. fumigatus...
3.
Zhou W, Warrilow A, Thomas C, Ramos E, Parker J, Price C, et al.
Biochim Biophys Acta Mol Cell Biol Lipids
. 2018 Jul;
1863(10):1164-1178.
PMID: 30044954
The sterol metabolome of Acanthamoeba castellanii (Ac) yielded 25 sterols. Substrate screening of cloned AcCYP51 revealed obtusifoliol as the natural substrate which converts to ∆-sterol (<95%). The combination of [H-methyl]methionine...
4.
and Efficacy of a Novel and Long-Acting Fungicidal Azole, PC1244, on Aspergillus fumigatus Infection
Colley T, Sehra G, Chowdhary A, Alanio A, Kelly S, Kizawa Y, et al.
Antimicrob Agents Chemother
. 2018 Feb;
62(5).
PMID: 29439966
The antifungal effects of the novel triazole PC1244, designed for topical or inhaled administration, against were tested in a range of and studies. PC1244 demonstrated potent antifungal activities against clinical...
5.
Hull C, Warrilow A, Rolley N, Price C, Donnison I, Kelly D, et al.
Biotechnol Biofuels
. 2017 Oct;
10:226.
PMID: 29021826
Background: Bioethanol production from sustainable sources of biomass that limit effect on food production are needed and in a biorefinery approach co-products are desirable, obtained from both the plant material...
6.
Warrilow A, Parker J, Price C, Garvey E, Hoekstra W, Schotzinger R, et al.
Antimicrob Agents Chemother
. 2017 May;
61(7).
PMID: 28483956
Prior to characterization of antifungal inhibitors that target CYP51, CYP51 was expressed in , purified, and characterized. CYP51 bound lanosterol, obtusifoliol, and eburicol with similar affinities (dissociation constant [ ]...
7.
Colley T, Alanio A, Kelly S, Sehra G, Kizawa Y, Warrilow A, et al.
Antimicrob Agents Chemother
. 2017 Feb;
61(5).
PMID: 28223388
The profile of PC945, a novel triazole antifungal designed for administration via inhalation, was assessed in a range of and studies. PC945 was characterized as a potent, tightly binding inhibitor...
8.
Warrilow A, Price C, Parker J, Rolley N, Smyrniotis C, Hughes D, et al.
Sci Rep
. 2016 Jun;
6:27690.
PMID: 27291783
Malassezia globosa cytochromes P450 CYP51 and CYP5218 are sterol 14α-demethylase (the target of azole antifungals) and a putative fatty acid metabolism protein (and a potential azole drug target), respectively. Lanosterol,...
9.
Warrilow A, Parker J, Price C, Nes W, Garvey E, Hoekstra W, et al.
Antimicrob Agents Chemother
. 2016 May;
60(8):4530-8.
PMID: 27161631
Cryptococcosis is a life-threatening disease often associated with HIV infection. Three Cryptococcus species CYP51 enzymes were purified and catalyzed the 14α-demethylation of lanosterol, eburicol, and obtusifoliol. The investigational agent VT-1129...
10.
Warrilow A, Parker J, Price C, Nes W, Kelly S, Kelly D
Antimicrob Agents Chemother
. 2015 Oct;
59(12):7771-8.
PMID: 26459890
The incidence of triazole-resistant Aspergillus infections is increasing worldwide, often mediated through mutations in the CYP51A amino acid sequence. New classes of azole-based drugs are required to combat the increasing...